Toxic influence of subchronic paraquat administration on dopaminergic neurons in rats

Brain Research

Volumn 1155, Issue 1, 2007, Pages 196-207

  Kuter, Katarzyna ^a   Śmiałowska, Maria ^a   Wierońska, Joanna ^a   Zieba, Barbara ^a   Wardas, Jadwiga ^a   Pietraszek, Małgorzata ^a   Nowak, Przemysław ^b   Biedka, Izabela ^b   Roczniak, Wojciech ^b   Konieczny, Jolanta ^a   Wolfarth, Stanisław ^a   Ossowska, Krystyna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

degeneration; dopaminergic neurons; GAD67 mRNA; paraquat; Parkinson's disease; proenkephalin mRNA

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; 3,4 DIHYDROXYPHENYLACETIC ACID; 4 AMINOBUTYRIC ACID; DOPAMINE; DOPAMINE DERIVATIVE; DOPAMINE TRANSPORTER; GLUTAMATE DECARBOXYLASE 67; HOMOVANILLIC ACID; MESSENGER RNA; NORADRENALIN; PARAQUAT; PESTICIDE; PROENKEPHALIN; SEROTONIN; TOXIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; GABAERGIC SYSTEM; GABAERGIC TRANSMISSION; IMMUNOREACTIVITY; MALE; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; NORADRENERGIC SYSTEM; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PUTAMEN; RAT; SEROTONINERGIC SYSTEM; SEROTONINERGIC TRANSMISSION; SUBSTANTIA NIGRA;

ANIMALS; CAUDATE NUCLEUS; DOPAMINE; DRUG ADMINISTRATION SCHEDULE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUTAMATE DECARBOXYLASE; HERBICIDES; ISOENZYMES; NERVE DEGENERATION; NEURONS; PARAQUAT; PARKINSONIAN DISORDERS; PUTAMEN; RATS; RNA, MESSENGER;

RATTUS;

EID: 34250010917     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.04.018     Document Type: Article

References (62)

1. 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Neurol. Sci. 24 (2003) 149-150
2. Asanuma M., Miyazaki I., and Ogawa N. Dopamine- or l-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in model of Parkinson's disease. Neurotox. Res. 5 (2003) 165-176
3. 2 signaling in the nigrostriatal dopamine pathway via ATP-sensitive potassium channels: issues and answers. Antioxid. Redox Signal. 9 (2007) 219-231
4. Balcioglu A., Zhang K., and Tarazi F.I. Dopamine depletion abolishes apomorphine- and amphetamine-induced increases in extracellular serotonin levels in the striatum of conscious rats: a microdialysis study. Neuroscience 119 (2003) 1045-1053
5. Barlow B.K., Thiruchelvam M.J., Bennice L., Cory-Slechta D.A., Ballatori N., and Richfield E.K. Increased synaptosomal dopamine content and brain concentration of paraquat produced by selective dithiocarbamates. J. Neurochem. 85 (2003) 1075-1086
6. Bezard E., Gross C.E., and Brotchie J.M. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci. 26 (2003) 215-220
7. Brooks A.I., Chadwick C.A., Gelbard H.A., Cory-Slechta D.A., and Federoff H.J. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res. 823 (1999) 1-10
8. Carta A.R., Pinna A., Cauli O., and Morelli M. Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic intermittent l-DOPA and A2A receptor blockade plus l-DOPA in dopamine-denervated rats. Synapse 44 (2002) 166-174
9. +, oxidant and specific neurotoxicants shares the common molecular mechanism. J. Neurochem. 76 (2001) 1010-1021
10. Cicchetti F., Lapointe N., Roberge-Tremblay A., Saint-Pierre M., Jimenez L., Ficke B.W., and Gross R.E. Systemic exposure to paraquat and maneb models early Parkinson's disease in young adult rats. Neurobiol. Dis. 20 (2005) 360-371
11. Corasaniti M.T., and Nisticò G. Determination of paraquat in rat brain by high-performance liquid chromatography. J. Chromatogr. 643 (1993) 419-425
12. Dalley J.W., Cardinal R.N., and Robbins T.W. Prefrontal executive and cognitive functions in rodents; neural and neurochemical substrates. Neurosci. Biobehav. Rev. 28 (2004) 771-784
13. Davis G.C., Williams A.C., Markey S.P., Ebert M.H., Caine E.D., Rechert C.M., et al. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1 (1979) 9249-9254
14. Di Monte D.A., Lavasani M., and Manning-Bog A.B. Environmental factors in Parkinson's disease. Neurotoxicology 23 (2002) 487-502
15. Dziedzicka-Wasylewska M., and Rogóż R. The effect of prolonged treatment with imipramine and electroconvulsive shock on the levels of endogenous enkephalins in the nucleus accumbens and the ventral tegmentum of the rat. J. Neural Transm. Gen. Sect. 102 (1995) 221-228
16. Ehringer H., and Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wochenschr. 38 (1960) 1236-1239
17. Fukuda H., Hara K., Nakamura S., Kimura H., and Kameyama M. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) enhances tryptophan hydroxylase activity in mouse striatum, but not in the frontal cortex. Brain Res. 449 (1988) 399-402
18. Fukushima T., Yamada K., Hojo N., Isobe A., Shiwaku K., and Yamane Y. Mechanism of cytotoxicity of paraquat. III. The effect of acute paraquat exposure on the electron transport system in rat mitochondria. Exp. Toxicol. Pathol. 46 (1994) 437-441
19. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma Jr. F.J., and Sibley D.R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250 (1990) 1429-1432
20. Gundersen H.J.G., and Jensen E.B. The efficiency of systematic sampling in stereology and its prediction. J. Microsc. 147 (1987) 229-263
21. Hara K., Tohyama I., Kimura H., Fukuda H., Nakamura S., and Kameyama M. Reversible serotonergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse striatum studied by neurochemical and immunohistochemical approaches. Brain Res. 410 (1987) 371-374
22. +)-analogs on the respiratory chain of bovine heart mitochondria. Arch. Biochem. Biophys. 337 (1997) 69-74
23. Hertzman C., Wiens M., Bowering D., Snow B., and Calne D. Parkinson's disease: a case-control study of occupational and environmental risk factors. Am. J. Ind. Med. 17 (1990) 349-355
24. Karstaedt P.J., Kerasidis H., Pincus J.H., Meloni R., Graham J., and Gale K. Unilateral destruction of dopamine pathways increases ipsilateral striatal serotonin turnover in rats. Exp. Neurol. 126 (1994) 25-30
25. A receptors subunits in the substantia nigra, pars reticulata. Neuroscience 132 (2005) 833-842
26. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
27. Laprade N., and Soghomonian J.-J. Differential regulation of mRNA encoding for the two isoforms of glutamate decarboxylase (GAD65 and GAD67) by dopamine receptors in the rat striatum. Mol. Brain Res. 34 (1995) 65-74
28. Levy R., Herrero T., Ruberg M., Villares J., Faucheux B., Guridi J., Guillen J., Luquin M.R., Javoy-Agid F., Obeso J.A., Agid Y., and Hirsch E.C. Effects of nigrostriatal denervation and l-DOPA therapy on the GABAergic neurons of the striatum in MPTP-treated monkeys and Parkinson's disease: an in situ hybridization study of GAD67 mRNA. Eur. J. Neurosci. 7 (1995) 1199-1209
29. Lindefors N. Dopaminergic regulation of glutamic acid decarboxylase mRNA expression and GABA release in the striatum: a review. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 17 (1993) 887-903
30. 14C]diquat in frogs and mice: accumulation in neuromelanin. Neurosci. Lett. 93 (1988) 1-6
31. Liou H.H., Tsai M.C., Chen C.J., Jeng J.S., Chang Y.C., Chen S.Y., and Chen R.C. Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology 48 (1997) 1583-1588
32. Lucas G., De Deurwaerdére P., Porras G., and Spampinato U. Endogenous serotonin enhances the release of dopamine in the striatum only when nigro-striatal dopaminergic transmission is activated. Neuropharmacology 39 (2001) 1984-1995
33. Maeda T., Kannari K., Shen H., Arai A., Tomiyama M., Matsunaga M., and Suda T. Rapid induction of serotonergic hyperinnervation in the adult rat striatum with extensive dopaminergic denervation. Neurosci. Lett. 343 (2003) 17-20
34. Maeda T., Nagata K., Yoshida Y., and Kannari K. Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA. Brain Res. 1046 (2005) 230-233
35. Marien M., Lategan A., and Colpaert F. Noradrenergic control of striatal dopamine release. In: Briley M., and Marien M. (Eds). Noradrenergic Mechanisms in Parkinson's Disease (1994), CRc Press, Boca Raton 130-158
36. Mattson M.P., Maudsley S., and Martin B. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci. 27 (2004) 589-594
37. McCormack A.L., Thiruchelvam M., Manning-Bog A.B., Thiffault C., Langston J.A., Cory-Slechta D.A., and Di Monte D.A. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol. Dis. 10 (2002) 119-127
38. McCormack A.L., Atienza J.G., Langston J.W., and Di Monte D.A. Decreased susceptibility to oxidative stress underlies the resistance of specific dopaminergic cell populations to paraquat-induced degeneration. Neuroscience 141 (2006) 929-937
39. 3H-GBR 12935. J. Neural. Transm.: Gen. Sect. 87 (1992) 1-14
40. Moore H., Todd C.L., and Grace A.A. Striatal extracellular dopamine levels in rats with haloperidol-induced depolarization block of substantia nigra. J. Neurosci. 18 (1998) 5068-5077
41. Ohta K., Ohta M., Mizuta I., Fujinami A., Shimazu S., Sato N., Yoneda F., Hayashi K., and Kuno S. The novel catecholaminergic and serotonergic activity enhancer R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane up-regulates neurotrophic factor synthesis in mouse astrocytes. Neurosci. Lett. 328 (2002) 205-208
42. Ossowska K., Wardas J., Kuter K., Nowak P., Da{ogonek}browska J., Bortel A., Labus Ł., Krygowska-Wajs A., and Wolfarth S. The influence of paraquat on dopaminergic transporter in rats. Pharmacol. Rep. 57 (2005) 342-347
43. Ossowska K., Wardas J., Śmiałowska M., Kuter K., Lenda T., Wierońska J.M., Zie{ogonek}ba B., Nowak P., Da{ogonek}browska J., Bortel A., Kwieciński A., and Wolfarth S. A slowly developing dysfunction of dopaminergic nigrostriatal neurons induced by long-term paraquat administration in rats: an animal model of preclinical stages of Parkinson's disease?. Eur. J. Neurosci. 22 (2005) 1294-1304
44. Ossowska K., Śmiałowska M., Kuter K., Wierońska J., Zie{ogonek}ba B., Wardas J., Nowak P., Da{ogonek}browska J., Bortel A., Biedka I., Schulze G., and Rommelspacher H. Degeneration of dopaminergic mesocortical neurons and activation of compensatory processes induced by a long-term paraquat administration in rats; implications for Parkinson's disease. Neuroscience 141 (2006) 2155-2165
45. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1986), Academic Press, New York
46. Rozas G., Liste I., Guerra M.J., and Labandeira-Garcia J.L. Sprouting of the serotonergic afferents into striatum after selective lesion of the dopaminergic system by MPTP in adult mice. Neurosci. Lett. 245 (1998) 151-154
47. Schmuck G., Ro{double acute}hrdanz E., Tran-Thi Q.-H., Kahl R., and Schlüter G. Oxidative stress in rat cortical neurons and astrocytes induced by paraquat in vitro. Neurotox. Res. 4 (2002) 1-13
48. Shepherd K.R., Lee E.-S.Y., Schmued L., Jiao Y., Ali S.F., Oriaku E.T., Lamango N.S., Soliman K.F.A., and Charlton C.G. The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice. Pharmacol. Biochem. Behav. 83 (2006) 349-359
49. Shimizu K., Ohtaki K., Matsubara K., Aoyama K., Uezono T., Saito O., Suno M., Ogawa K., Hayase N., Kimura K., and Shiono H. Carrier-mediated processes in blood-brain penetration and neuronal uptake of paraquat. Brain Res. 906 (2001) 135-142
50. Shimizu K., Matsubara K., Ohtaki K., Fujimaru S., Saito O., and Shiono H. Paraquat induces long-lasting dopamine overflow through the excitotoxic pathway in the striatum of freely moving rats. Brain Res. 976 (2003) 243-252
51. Soghomonian J.J., Gonzales C., and Chesselet M.-F. Messenger RNAs encoding glutamate-decarboxylase are differentially affected by nigrostriatal lesions in subpopulations of striatal neurons. Brain Res. 576 (1992) 68-79
52. Sterio D.C. The unbiased estimation of number and sizes of arbitrary particles using the dissector. J. Microsc. 134 (1984) 127-136
53. Thiruchelvam M., Brockel B.J., Richfield E.K., Baggs R.B., and Cory-Slechta D.A. Potential and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease?. Brain Res. 873 (2000) 225-234
54. Thiruchelvam M., Richfield E.K., Baggs R.B., Tank A.W., and Cora-Slechta D.A. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J. Neurosci. 20 (2000) 9207-9214
55. Thiruchelvam M., McCormack A., Richfield E.R., Baggs R.B., Tank A.W., Di Monte D.A., and Cory-Slechta D.A. Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. Eur. J. Neurosci. 18 (2003) 589-600
56. Thiruchelvam M., Powers J.M., Cory-Slechta D.A., and Richfield E.K. Risk factors for dopaminergic neurons loss in human α-synuclein transgenic mice. Eur. J. Neurosci. 19 (2004) 845-854
57. Thomas D.M., Walker P.D., Benjamins J.A., Geddes T.J., and Kuhn D.M. Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J. Pharmacol. Exp. Ther. 311 (2004) 1-7
58. Wardas J., Pietraszek M., Wolfarth S., and Ossowska K. The role of metabotropic glutamate receptors in regulation of striatal proenkephalin expression; implications for the therapy of Parkinson's disease. Neuroscience 122 (2003) 747-756
59. 2. FEBS Lett. 128 (1981) 339-342
60. Wolf O.T., Dyakin V., Patel A., Vadasz C., De Leon M.J., McEwen B.S., and Bulloch K. Volumetric structural magnetic resonance imaging (MRI) of the rat hippocampus following kainic acid (KA) treatment. Brain Res. 934 (2002) 87-96
61. Wolfarth S., Konieczny J., Śmiałowska M., Schulze G., and Ossowska K. Influence of 6-hydroxydopamine lesion of the dopaminergic nigrostriatal pathway on the muscle tone and electromyographic activity measured during passive movements. Neuroscience 74 (1996) 985-996
62. Wood P.L., Kim H.S., and Marien M.R. Intracerebral dialysis: direct evidence for the utility of 3-MT measurements as an index of dopamine release. Life Sci. 41 (1987) 1-5